BriaCell Reports Sustained Cancer-Cell Killing With Bria-OTS+ in Preclinical Studies

Bitget2026/11/06 14:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BriaCell Therapeutics and majority-owned BriaPro announced preclinical immunotherapy findings for presentation in four posters at SITC on Nov. 6-7, 2026.
Bria-OTS+ activated immune responses across multiple cancer models, with sustained cancer-cell killing supporting continued development in breast and prostate cancers.
BriaPro's BP-80 was well tolerated in a nonhuman primate study, with no treatment-related pathological findings.
TILsRx-001 counteracted immune inhibition in laboratory testing; engineered CD80 variants showed stronger binding to a checkpoint target, supporting further development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060900PRIMZONEFULLFEED9872089) on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to Bloomberg, CoreWeave is seeking to refinance at least 4 billion USD through an investment-grade loan, led by Morgan Stanley and Mitsubishi UFJ, with a syndication roadshow expected to start as soon as next week. This financing continues the structure of using Nvidia chips and customer contracts as collateral, with the yield on the issuance anticipated to be around 7% to 7.5%, much lower than its junk bond yield. Following the news, CoreWeave's shares fell nearly 5.8% after hours.

华尔街见闻•2026/11/11 23:46

CoreWeave plans to issue at least $4 billion in investment-grade loans, falling nearly 6% after hours

Outperformed the S&P by 19.2 percentage points in one month: Berkshire (BRK.B) achieves its highest monthly relative advantage since 2010, second only to the 2008 financial crisis

As the AI trading boom subsides and technology stocks waver, one of the market’s oldest “safe havens” has once again proven its value. Berkshire Hathaway (BRK.B) has just recorded one of its most notable relative gains in over a decade.

智通财经•2026/11/11 23:46